A profound decrease in activity of the mitochondrial enzyme cytochrome oxidase in blood platelets is a recently identified concomitant of Alzheimer's disease (AD). We investigated a possible pathogenic link between this finding and the symptoms of AD by mimicking this mitochondrial enzyme deficiency in rats. Rats were infused chronically with a selective inhibitor of cytochrome oxidase, sodium azide, or with saline delivered via subcutaneously implanted osmotic minipumps. The azide treatment impaired both spatial and nonspatial learning. Further, the azide treatment inhibited a low-threshold form of hippocampal long-term potentiation, primed burst potentiation. The behavioral deficits were not secondary to a sensory or motor impairment. Thus, chronic azide treatment of rats models some characteristics of AD. (J Geriatr Psychiatry Neurol 1992;5:93–101).
Get full access to this article
View all access options for this article.
References
1.
1. Corkin S: Some relationships between global amnesias and the memory impairment in Alzheimer's disease, in Corkin S, Growdon JH, Usdin E, Wurtman RJ (eds): Alzheimer's Disease: A Report of Progress, vol 9. New York, Raven Press, 1982, pp 149–164.
2.
2. Smith G: Animal models of Alzheimer's disease: Experimental cholinergic denervation. Brain Res1988; 472:103–118.
3.
3. McLachlan DRC: Aluminum and Alzheimer's disease. Neurobiol Aging1987; 7:525–557.
4.
4. Peterson C, Gibson GE, Blass JP: Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease. N Engl J Med1985; 312:1063–1065.
5.
5. Peterson C, Goldman JE: Alterations in calcium content in cultured skin fibroblasts from aged and Alzheimer's donors. Proc Natl Acad Sci USA1986; 83:2758–2762.
6.
6. Sims NR, Finegan JM, Blass JP: Altered glucose metabolism in fibroblasts from patients with Alzheimer's disease. N Engl J Med1985; 313:638–639.
7.
7. Sims NR, Finegan JM, Blass JP: Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol1987; 21:451–457.
8.
8. Sims NR, Finegan JM, Blass JP, et al: Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res1987; 436:30–38.
9.
9. Terry RD, Katzman R: Senile dementia of the Alzheimer type. Ann Neurol1983; 14:497–505.
10.
10. Parker WD Jr, Filley CM, Parks JK: Cytochrome oxidase deficiency in Alzheimer's disease. Neurology1990; 40:1302–1303.
11.
11. Ball MJ, Fisman M, Hachinski V, et al: A new definition of Alzheimer's disease: A hippocampal dementia. Lancet1985; 1:14–16.
12.
12. Berger TW, Thompson RF: Identification of pyramidal cells as the critical elements in hippocampal plasticity during learning. Proc Natl Acad Sci USA1978; 75:1572–1576.
13.
13. Scoville WB, Milner B: Loss of recent memory after bilateral hippocampal lesions. Neurosurg Psychiatry1957; 20:11–21.
14.
14. Squire LR: Mechanisms of memory. Science1986; 232:1612–1619.
15.
15. Zola-Morgan S, Squire LR: Memory impairment in monkeys following lesions limited to the hippocampus. Behav Neurosci1986; 100:155–160.
16.
16. Lynch G, Baudry MP: The biochemistry of memory: A new and specific hypothesis. Science1984; 224:1057–1062.
18. Diamond DM, Dunwiddie TV, Rose GM: Characteristics of hippocampal primed burst potentiation in vitro and in the awake rat. J Neurosci1988; 8:4079–4088.
19.
19. Rose GM, Dunwiddie TV: Induction of hippocampal long-term potentiation using physiologically patterned stimulation. Neurosci Lett1986; 69:244–248.
20.
20. Larson J, Wong D, Lynch G: Patterned stimulation at the theta frequency is optimal for the induction of hippocampal long-term potentiation. Brain Res1986; 368:347–350.
21.
21. Barnes CA, Nadel L, Honig WK: Spatial memory deficit in senescent rats. Can J Psychol1980; 34:29–39.
22.
22. Diamond DM, Bennett MC, Stevens KE, et al: Exposure to a novel environment interferes with the induction of hippocampal primed burst potentiation. Psychobiology1990; 18:273–281.
23.
23. Diamond DM, Bennett MC, Engstrom DA, et al: Adrenalectomy reduces the threshold for hippocampal primed burst potentiation in the anesthetized rat. Brain Res1989; 492:356–360.
24.
24. Anderson P, Bliss TVP, Skrede KK: Unit analysis of hippocampal population spikes. Exp Brain Res1971; 13:208–221.
25.
25. Clark JB, Nicklas WJ: The metabolism of rat brain mitochondria: Preparation and characterization. J Biol Chem1970; 245:4724–4731.
26.
26. Whitfield CD, Bostedor R, Goodrum D, et al: Hamster cell mutants unable to grow on galactose and exhibiting an overlapping complementation pattern are defective in the electron transport chain. J Biol Chem1981; 256:6651–6656.
27.
27. Stumpf DA, Parks JK: Human mitochondrial electron transport chain: Assay of succinate cytochrome c reductase in leucocytes. Biochem Med1981; 25:234–238.
29. Clark GD: Role of excitatory amino acids in brain injury caused by hypoxia-ischemia, status epilepticus and hypoglycemia. Clin Perinatol1989; 16:459–474.
31. Chandrasekaran K, Matocha MF, Stoll J, et al: Analysis of mRNA showing region-specific expression in nonhuman primate cortex. Neurosci Abstr1990; 16:344.
32.
32. Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol1990; 26:719–723.
33.
33. Langston JW, Ballard P, Tetrud JW, Irvin I: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science1983; 219:979–980.
34.
34. Ramsey RR, Salach JI, Singer TP: Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun1986; 134:743–748.
35.
35. Ramsey RR, Singer TP: Energy dependent uptake of? N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem1986; 261:7585–7587.
36.
36. Vyars I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite N-methyl-4-phenylpyridinium. J Neurochem1986; 46:1501–1507.
37.
37. Stumpf DA: Mitochondrial multisystem disorders: Clinical, biochemical and morphologic features?Curr Neurol1979; 2:117–149.
38.
38. Blass JP, Sheu RK, Cedarbaum JM: Energy metabolism in disorders of the nervous system. Rev Neurol1988; 144:543–563.
39.
39. Stryker L: Chapter 12: Glycolysis, in Biochemistry. W.H. Freeman and Company, San Francisco, 1975, p 294.
40.
40. Gibson GE, Blass JP: Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem J1975; 148:17–23.
41.
41. Gibson GE, Blass JP: Impaired synthesis of acetylcholine in brain accompanying mild hypoxia and hypoglycemia. J Neurochem1976; 27:37–42.
42.
42. Gibson GE, Peterson C: Aging decreases oxidative metabolism and the release and synthesis of acetylcholine. J Neurochem1981; 37:978–984.
43.
43. Whitehouse PJ, Price DL, Clark AW, et al: Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol1981; 10:122–126.
44.
44. Lehninger AL: Chapter 16: The tricarboxylic acid cycle and the phosphogluconate pathway, in Biochemistry. Worth Publishers, Inc, New York, 1970; p 439.
45.
45. Pelligrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F: Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci1990; 10:1035–1041.
46.
46. Greenamyre JT, Young AB: Excitatory amino acids and Alzheimer's disease. Neurobiol Aging1990; 10:593–602.
48. Imlay JA, Linn S: DNA damage and oxygen radical toxicity. Science1988; 240:1302–1309.
49.
49. Halliwell B: Oxidants in the central nervous system: Some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic damage or stroke??Acta Neurol Scand Suppl1989; 126:23–33.
50.
50. Anderson S, Sankier AT, Barrell G, et al: Sequence and organization of the human mitochondrial genome. Nature1981; 90:457–465.
51.
51. Bolhuis PA, Bleeker-Wagemakers NJ, Ponne NJ, et al: Rapid shift in genotype of human mitochondrial DNA in a family with Leber's hereditary optic neuropathy. Biochem Biophys Res Commun1990; 170:994–997.
52.
52. Holt IJ, Miller DH, Harding AE: Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's heriditary optic neuropathy. J Med Genet1989; 26:739–743.
53.
53. Shoffner JM, Lott MT, Lezza AMS, et al: Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNAlys mutation. Cell1990; 61:931–937.
